Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
25.55
+0.12 (0.47%)
Nov 17, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

ADHD is the fastest-growing segment, with Jornay and Azstarys supporting continued growth and total portfolio revenue expected at $825M-$855M this year. Pain products are expected to be broadly stable, while Belbuca’s 2027 outlook depends on generic entry risk.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Hi, good morning. Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies. I have the wonderful pleasure of having Collegium Pharmaceutical here. I have the CFO, Colleen Tupper, as well as Ian Karp, IR. Maybe just first off, give us a big picture overview around Collegium, some of the progress you guys have made this year, and maybe talk about your outlook into 2027.

Colleen Tupper
CFO, Collegium Pharmaceutical

Great. Thanks, Dennis, and thanks for having us. Collegium is a dynamic biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions. There are three main components to our business model. That's we identify differentiated medicines that address meaningful patient needs, we apply focused commercial execution to accelerate growth, and we create value through strategic acquisition and then seamless integration. To date, we've built the industry's leading organization to responsibly support the management of severe chronic pain, and most recently, we've expanded into ADHD. Can we go one more up? While our pain portfolio remains an important foundation of the company, ADHD now represents the fastest-growing segment of our business and generates approximately 36% of total revenues. Our first ADHD medicine, Jornay PM, grew 48% in 2025, and we expect about 31% growth this year, with revenues between $190 million and $200 million.

In May of this past year, we acquired our second ADHD medicine, Azstarys, a highly complementary offering to Jornay, and it's expected to deliver between $65 million and $75 million in its first partial year, with further growth expected in 2027 and beyond. In our most recent quarter, our first full quarter of owning Azstarys, we have seen prescription volumes return to growth following an overall decline in 2025. Our total diversified portfolio of medicines is expected to generate between $825 to $855 million of revenue this year, approximately 8% growth year-over-year. Importantly, our business continues to be highly profitable, with an adjusted EBITDA margin of over 50%, well above typical norms in specialty pharma space.

Looking ahead, we remain focused on driving growth in ADHD and maximizing the performance of our pain portfolio, and deploying capital in a thoughtful manner through business development, debt reduction, and opportunistically buying shares back.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Perfect. ADHD has obviously been a big growth driver for you, and you guys have around 190 reps on the ground. Do you think that is optimized now that you have integrated Azstarys into the business? Now that you have two products, does that actually open up more opportunities in these doctors' offices for you guys?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah, we do believe our commercial organization is the right size and have no current plans to increase the number of our sales reps. We have an efficient single sales force selling both products, and they are focused on activating healthcare providers and increasing the depth of prescribing. Based on our growth opportunities in ADHD, we have increased our sales force size two times in the past two years, first going from 125 reps up to 180, and then most recently, following the acquisition of Azstarys, increasing to about 190 territories. We are targeting about 27,000 healthcare providers for both Azstarys and Jornay, and we have heard from physicians in the early days of having both products available to them that they really find it to be an efficient call, and they do like hearing about both products in one call.

Our targeted patient and caregiver outreach, particularly through social media platforms, has successfully increased awareness and trial for Jornay PM and represents an additional opportunity to support growth across both brands.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Can you explain the different types of patients that would go on to Jornay versus Azstarys, and is there a major distinction between those types of patients?

Ian Karp
Head of Investor Relations, Collegium Pharmaceutical

Yeah, sure. Maybe I will take that one. Jornay and Azstarys really are differentiated and complementary medicines, so it is important to keep that context in mind. They really do target different types of patients, which allow us to really help a broad set of patients. Both medicines can last all day. They offer a smooth offset, which is particularly important as it can help avoid what is sometimes known as a treatment crash, which can be seen with other ADHD medicines. But the main differences between the two, really around the timing of their symptom control. Jornay PM is the first and only stimulant that is delivered at night, okay? So you take it typically before bedtime, and it delivers symptom control upon the patient awakening. This can be particularly important for patients who have really problematic ADHD symptoms first thing in the morning.

For a child or adolescent, that could mean a difficult time getting up in the morning, getting to school, so taking your Jornay at night and having it work immediately upon awakening can really be beneficial to those patients. Azstarys works a bit differently. It is the only medicine that has both a fast-acting and long-acting ADHD medicine in one capsule. That is typically preferred by the patient who has a bit more variability in their schedule, so they may not necessarily be getting up at the exact same time every day. But when they do need their symptom control, they need it to begin working as quickly as possible, and oftentimes they need that lasting throughout the day. That is generally where Azstarys is positioned.

Both have, I would say, very strong perceptions by healthcare providers, and part of that has been the marketing efforts that we have undertaken since acquiring Jornay two years ago, and we are just really getting going now with Azstarys, as it came into our portfolio just this past May.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

How do you guys think about balancing promotion between these two products with doctors?

Colleen Tupper
CFO, Collegium Pharmaceutical

It can be sometimes physician-dependent. There certainly are physicians that we can see through the data have prescribed more of Azstarys and/or more of Jornay. As each rep is planning their individual call to that physician, they will tailor it to its needs based on their prescribing habits. Also, if there are physicians that have not prescribed one or the other, then they are making sure that they are well-informed about that additional product.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. For Jornay specifically, you have had the asset for several years now.

You guys have seen a lot of revenue growth. I would say part of that growth was driven by pricing, right? Are we at a generally stable gross-to-net today, or could that further be optimized potentially in 2027 or 2028?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah. For Jornay PM, we are expecting gross-to-nets full year to be in the mid-60% range, and we are tracking well to that year-to-date, to that expectation. As you note, that is a marked improvement from when we acquired the product in 2024. Full year gross-to-net was about 71%, and we have continuously improved that. While we will continuously look for ways to improve profitability, I would say there is more stabilization in Jornay than there has been. We do not expect a marked, significant reduction going forward. Between 2025 and 2026, it is about stable.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. For Azstarys?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah. For Azstarys, we acquired the product with gross-to-nets in the low 70s as well, and that's where they currently remain, just a few quarters in. Over time, we do believe there is an opportunity to continue to optimize, but with Azstarys, I would say it's more incremental in nature, and it will be a bit more time to do so. I don't think you would expect to see as significant of a step-down over the short period of time as we did with Jornay.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. For Azstarys, the gross margins on that are a little bit lower than what we are used to for a small molecule, I think high 70s, low 80s. Maybe talk a little bit about that. What is driving that gross margin, and what are you guys doing to potentially improve that?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah. So, overall, from a net margin perspective, obviously gross-to-nets and copay is a big component of that.

That remains true for both Azstarys and Jornay. As far as the cost of manufacturing, Azstarys is more expensive to manufacture than Jornay, but we do have initiatives in place, in fact, initiatives that were started under prior ownership, to reduce some of those costs in the future. Importantly, across both the products, they do have attractive gross margin. We do have a few milestones associated with the initial acquisition of Azstarys, for a grand total of about $135 million of additional payments. Three of the milestones are related to future sales expectations, or performance levels, rather, and two are related to those improvements in manufacturing process.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. Why exactly is it more difficult to manufacture Azstarys? Is it with the API, or?

Colleen Tupper
CFO, Collegium Pharmaceutical

It is the overall process, inclusive of the technology it is to produce it.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay.

Colleen Tupper
CFO, Collegium Pharmaceutical

It is in the total yield being generated. Those are the things that are already in flight to improve, which will increase efficiency, volume, as well as price.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. Then, as some of these things start to roll out, maybe by the end of 2027 or 2028, how much higher can gross margin go for Azstarys?

Colleen Tupper
CFO, Collegium Pharmaceutical

Great. I will look forward to quantifying it in future when we can guide you to that.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay.

Colleen Tupper
CFO, Collegium Pharmaceutical

We are expecting an improvement, but I will quantify it at a later date.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. If you look at Azstarys this year, appreciating that it has changed hands, but when I look at end-user revenue, it is probably $100 million, a little bit north of $100 million. Now that it is in your hands, how are you thinking about growth in Azstarys in 2027?

Ian Karp
Head of Investor Relations, Collegium Pharmaceutical

Yeah, maybe I'll take that one. We haven't provided guidance yet for 2027, but I think we can provide at least some color in terms of how we're thinking about the business next year. Last quarter was our very first full quarter selling Azstarys, and we were pleased. We had about $26.5 million in revenue last quarter, and importantly, that was up about 2% year-over-year. This is in contrast to last year, where Azstarys actually had declined by about 2% over the full year 2025. It was encouraging to see in our first full quarter, we've returned the brand to prescription growth.

We clearly have higher aspirations than 2% growth.

But as Colleen mentioned, we'll be in a better position, I think, as we move into January to talk about our expectations for full year 2027. You may recall, in the second quarter of this year, we increased our guidance by about $5 million. We're expecting $65 million-$75 million worth of Azstarys revenues this year from a partial year of our ownership. We believe there's meaningful potential to increase that over time.

I think more of that increase will come likely from volume and increased prescriptions. As Colleen mentioned, we do think there is some ability to improve gross-to-nets, and that'll evolve over time, and we'll talk more about that as we get closer.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. For both of these ADHD products, I mean, Jornay is probably going to do $200 million this year, Azstarys $65 million-$75 million, but you guys have never really given how you're thinking about peak sales for those two products. How would you characterize those products today now that you've had a little bit more experience?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah, I'm not going to break any news today with peak sales expectations. However, if you look across, yourself included, the analyst models, for Jornay particularly, I know they're pinning peak sales between the $300 million and $500 million range. I think that's reasonable. It's obviously a bit of a wide range.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

That's pretty wide.

Colleen Tupper
CFO, Collegium Pharmaceutical

It's a wide range, and there's no reason for either of these products to have a diminished growth profile going forward.

The IP for Jornay goes into 2032, and for Azstarys goes into the end of 2037. The ADHD market continues to grow. It is growing today at a compound annual growth rate of about 8%. These branded products will continue to be able to grow, and they importantly, in such a large market, about 111 million prescriptions written annually, the vast majority of that is generics. These products both source from generics as patients are cycling through therapy and trying to find the right medicine for them. Without answering your peak sales question, there is a strong growth trajectory expected to continue.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. $300 million to $500 million.

Colleen Tupper
CFO, Collegium Pharmaceutical

That is what the analyst models say for Jornay.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

We need to do a better job of modeling. Maybe if we can switch over to the pain portfolio. I mean, you guys have Belbuca, Xtampza, Nucynta. How would you characterize the growth of all those three products, maybe 2026?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah, so recently, as you've seen, Nucynta has experienced generic competition. We do have authorized generic partner in place for both the Nucynta IR and Nucynta ER products. We have seen, although earlier this year, we did have to let you know about unexpected additional pricing erosion on Nucynta, the volume has actually held up reasonably well, but we are now experiencing generic competition there. Looking forward, you would expect that that continues to decline at a moderated pace. Leaving with the pain portfolio, Xtampza and Belbuca, we expect that combined two products to be about stable going forward, and it continues to be a meaningful contributor to overall company performance and cash flows, and I think you'll see stability.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Mm-hmm. Okay.

Colleen Tupper
CFO, Collegium Pharmaceutical

For overall revenues.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Belbuca is a fairly important part of the pain franchise, right?

Remind us how you are thinking about generic competition there in 2027, and what underpins your confidence that one of the generic competitors will not launch at the beginning of the year?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah, so a lot going on there with Belbuca. In the most recent quarter, we had solid performance with revenues about flat to the prior quarter, and in the second quarter, we actually grew 10% over the prior year. We do view that there is limited risk of Belbuca near-term generic entrance, and to date, specifically related to Teva, who via a settlement has the ability to launch a generic version of Belbuca in January, on January 23, 2027. We have seen no specific signs that they plan to launch a generic. Strategically, they have taken a shift, and there is no market activity nor approval to date, but we watch that date very carefully. The next potential generic entrance would be Alvogen, which is currently barred from entering the market until December 2032, based on prior successful ANDA litigation, including an appeal.

Alvogen has recently filed a different and now second ANDA with the FDA, which they claim does not use our patent and technology. We are litigating Alvogen's second ANDA filed last year, and that trial is set for April of 2027. Our view of the strength of the Belbuca IP portfolio has not changed. We do remain confident in our patents and the court's previous rulings upholding the '539 patent, and we will continue to vigorously defend, including in May of this past year, we filed a citizen petition with the FDA to address certain legal and scientific issues raised by the new ANDA.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Sure. Maybe just remind us what Alvogen is kind of trying to do. As I understand, there is some pH backing layer situation that they are trying to navigate, right?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

When you are thinking about the case next year in April, what do you think are some of the different scenarios that could come out of that case, and how do you think that could impact Belbuca?

Colleen Tupper
CFO, Collegium Pharmaceutical

From an FDA perspective, I think what Alvogen is trying to do is they are leveraging our data for bioequivalence to proceed with getting approval for their new ANDA. On the other side of the coin, they are arguing to the courts, which have already upheld our patents, that it is a different product via some changes that they have made related to pH. Our view is, to be seen in court, but you cannot have both of those things be true. Our previous work on this is that pH is an important factor within the product.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Mm-hmm. Do you think Belbuca can grow in 2027?

Colleen Tupper
CFO, Collegium Pharmaceutical

I think overall, while we have not provided 2027 guidance, barring any generic entrant, which, as noted, we think would be a low probability, we would have revenues for Belbuca not too dissimilar to 2026 levels. We are encouraged that Belbuca recently secured formulary access for an additional 9 million lives starting in the fourth quarter of this year. But I would say you are talking about stable to low single-digit increase.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Stable to low single-digit. Okay.

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah, more to come when we guide for 2027.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. Yeah, I personally think that that's a really important dynamic because Belbuca is, what, $225 million in revenue? Like around there. That's a quarter of your total revenue almost, right? Maybe a little bit more. But consensus has you guys declining year-over-year, right?

Colleen Tupper
CFO, Collegium Pharmaceutical

Absolutely.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

I feel like there's a little bit of disconnect there because I think it could be flat to up, and versus consensus thinks that you guys will be down. I think we have a pretty good view on the durability of Belbuca for the next five, six years.

Colleen Tupper
CFO, Collegium Pharmaceutical

That's right. You point out an interesting dynamic between the models. Some of the models show exactly that, flat to growing, and then the others are accounting for what if a Teva does come in, and you see that fall off. I think the perspectives there that we've heard is it's much easier to increase your model if that event doesn't occur than to be in the other situation.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Mm-hmm. Okay. On Nucynta, do you have any additional color as it relates to the authorized generic that launched earlier this year?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah, we haven't seen. In the third quarter, we saw that pricing was pretty stable. That was the surprise that we communicated in our August earnings call for the second quarter, was that the authorized generic was being discounted far more than we had anticipated. That pricing has stabilized into the third quarter, and additionally, I would say our branded volumes for both the IR and ER products has been relatively stable for the past three months. I think that that's also a positive.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. Perfect. Maybe in the last couple minutes, if you take a step back and you look at Collegium as an entire company, you guys have done several BD deals over the last few years. You levered up, then you lever back down. From a valuation perspective, you guys are kind of stuck within this 4x-5x range. Having said that, what is your path to multiple expansion, and how should we think about BD or other more creative ways to drive multiple expansion?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah. We continue to execute well, and as you know, generate significant revenues, adjusted EBITDA, and cash. Importantly, we believe our growth prospects, particularly for our growth drivers, the ADHD products, are strong into the future. Our ADHD business continues to grow and is now accounting for about 36% of our overall sales. We see additional opportunities in 2027 and beyond, and importantly, have a longer IP life with those products. That said, as I sort of where I started in the beginning, our pain portfolio does remain a significant and highly profitable part of our portfolio, despite the generic erosion that we've experienced with Nucynta. We remain well-positioned for both future business development, as well as to further expand our business, as well as paying down our debt.

Now, I cannot fully point to an obvious explanation for the current valuation, but I can assure you that at Collegium, the team is intently focused on continuing to grow our business, increasing efficiencies, and better serving the needs of patients. We believe that if we continue to do those things well, our shareholders will also benefit in the long term. With that said, I'd say we continue to be open to and will explore other ways to drive shareholder value through potential strategic initiatives and various business development opportunities, all the while keeping a clean balance sheet. The cash generation of our business allows us to do that. As you've noted in the past, when we've used debt, we've levered up to consummate a transaction and then really aim to quickly delever and replenish that firepower.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Mm-hmm. Okay. In the last minute, just remind us your cash and debt and your leverage. Historically, you guys have done deals when you guys were below one times levered. Is that still kind of the case, or could you lever up further?

Colleen Tupper
CFO, Collegium Pharmaceutical

Yeah. At the end of the third quarter, our net debt over adjusted EBITDA is about two turns. Our guide for the year is about $450 million of EBITDA. So it gives you a little bit of sense of what room we have. I wouldn't say that there is a lower threshold by which we would only then do a deal. But we have sized, we would only be comfortable going up to about three turns net debt to EBITDA, but with the similar playbook of rapidly delevering back to that one turn-ish.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. Perfect. I think that's all the time that we have, but just great seeing you guys.

Colleen Tupper
CFO, Collegium Pharmaceutical

Thanks, Dennis.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Hope you guys have a good conference. Thank you.

Colleen Tupper
CFO, Collegium Pharmaceutical

Thanks a lot. You too. Thank you.